Regeneron Pharmaceuticals, Inc.

Q3 2026
Speakers

Oct 30, 2026 · 60 min

PREPARED REMARKS · INFERREDKeys: / search · Space play · ←→ ±10s · [] sections

Prepared remarks

Speaker 0

Unverified voice label

Welcome to the Regeneron Pharmaceuticals third quarter 2026 Earnings Conference Call. ?My name is Shannon and I will be your operator for today's call. At this time, all participants are in a listen-only mode. Later, we will conduct the question and answer session. Please note that this conference call is being recorded. ?I will now turn the call over to Ryan Crow, Senior Vice President of Vester Relations.

You may begin.

Passages & reports (5)
  • Welcome to the Regeneron Pharmaceuticals third quarter 2026 Earnings Conference Call.
  • My
  • name is Shannon and I will be your operator for today's call. At this time, all participan…
  • I
  • will now turn the call over to Ryan Crow, Senior Vice President of Vester Relations. You m…

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 1

Unverified voice label

you, Shannon. Good morning, good afternoon, and good evening to everyone listening around the world. Thank you for your interest in Regeneron and welcome to our third quarter 2026 earnings conference call. An archive and transcript of this call will be available on the Regeneron Investor Relations website shortly after our call concludes. Joining me on today's call are Dr. Leonard Schleifer, co-founder, board co-chair, president and chief executive officer, Dr.

George Yankopoulos, co founder, board co chair, president and chief scientific officer, Marion McCourt, Executive Vice President Commercial, and Chris Fenimore, Executive Vice President
Finance, and Chief Financial Officer. For our call today, Len will briefly review key third quarter performance drivers and highlight a few emerging pipeline programs. George will then detail our recent pipeline progress, followed by Marion, who will review our commercial performance, and finally, Chris will discuss our financial results and outlook.

After our prepared
remarks, the remaining time will be available for QA. ?I would like to remind you that remarks made on today's call may include forward-looking statements about Regenron. Such statements may include, but are not limited to those related to Regenron and its products and business, financial forecast and guidance, development programs, and related anticipated milestones, collaborations, finances, regulatory matters, payer covers and reimbursement, changes to drug pricing regulations and requirements, and our drug pricing strategy, intellectual property, pending litigation, and other proceedings and competition.

Each forward-looking statement is subject to risks and uncertainties that could cause actual results and events to differ materially from those projected in that statement.
?A more complete description of these and other material risks can be found in Regenron's filings with the United States Securities and Exchange Commission, including its Form 10 Q for the quarter-ended September 30th, 2026, which was filed with the SEC this morning.

Regenron does not undertake any obligation to update any forward-looking
statements, whether as a result of new information, future events, or otherwise. In addition, please note that GAP and non GAAP financial measures will be discussed on today's call. Information regarding our use of non GAP financial measures and a reconciliation of those measures to GAP is available in our quarterly results press release and our corporate presentation, both of which can be found on the Regenerant Investor Relations website.

Once our call concludes, the IR team will be available to answer any further questions. With that, let me turn the call over to our President and Chief Executive Officer, Dr. Leonard Schleifer. Len. Thank you, Ryan,
and

Passages & reports (12)
  • you, Shannon. Good morning, good afternoon, and good evening to everyone listening around …
  • on today's call are Dr. Leonard Schleifer, co-founder, board co-chair, president and chief…
  • Finance, and Chief Financial Officer. For our call today, Len will briefly review key thir…
  • remarks, the remaining time will be available for QA.
  • I
  • would like to remind you that remarks made on today's call may include forward-looking sta…
  • drug pricing regulations and requirements, and our drug pricing strategy, intellectual pro…
  • A
  • more complete description of these and other material risks can be found in Regenron's fil…
  • statements, whether as a result of new information, future events, or otherwise. In additi…
  • our corporate presentation, both of which can be found on the Regenerant Investor Relation…
  • and

Speaker 2

Unverified voice label

welcome to everyone ?joining our call today.

Passages & reports (3)
  • welcome to everyone
  • joining our call
  • today.

Speaker 1

We're

Passages & reports (1)
  • We're

Speaker unclear

?pleased to report another quarter of

Passages & reports (1)
  • pleased to report another quarter of

Speaker 2

strong performance, ?driven by outstanding commercial execution and a large and diverse pipeline that is continuing to deliver on its promise. Total revenue grew 36%, and non-gap earnings per share grew 70% compared to the third quarter of 2025. This marks our third consecutive quarter of double digit growth on both the top and bottom lines. Our commercial teams continue to execute at a very high level.

Dupixon, Kyle HD, and Liptio each set new all-time highs for quarterly net sales for the second quarter in a row. Dupixent global net sales in the third quarter,
as reported by Sinofi, reached a record six point five billion dollars, up thirty-five percent year over year at constant currency, which is truly remarkable for a medicine approaching 10 years on the market. ?In the US, where Dupixin is the leading biologic in eight of its nine approved FDA approved indications, quarterly net sales grew 40% and exceeded $5 billion for the first time, primarily driven by robust demand across all indications, as well as gross to net favorability as disclosed by Sonofi.

ALIA HD quarterly net sales in the U.S. reached a new all-time high of approximately 700 million, up 62% from a year ago, and now represent nearly two thirds of our U.S. retinal franchise. Physician unit demand grew
20% sequentially, reflecting the value retinal specialists and their patients see in extended dosing intervals, as well as last year's label enhancements, which added the retinal vein occlusion indication and greater dosing flexibility.

We remain optimistic for approval of the pre-filled
syringe before the end of the year, and we expect it to drive even further adoption if approved. LibTIO is making important differences for patients with skin and lung cancers, and it continues to build clinical and commercial momentum. In the US, it is the leading immunotherapy in non melanoma skin cancers and the second most prescribed immunotherapy in non-small cell lung cancer.

Global net sales reached a record $550 million, up 51% in constant currency, and U.S. net sales grew 81% to nearly
$400 million. Last week at ESMO, we presented longer-term data from our phase three C POST trial showing an increase in overall survival benefit with adjuvant lib tio and high-risk cutaneous squamous cell carcinoma, where it is the first and only approved immunotherapy.

Passages & reports (12)
  • strong performance,
  • driven by outstanding commercial
  • execution and a large and diverse pipeline that is continuing to deliver on its promise. T…
  • both the top and bottom lines. Our commercial teams continue to execute at a very high lev…
  • as reported by Sinofi, reached a record six point five billion dollars, up thirty-five per…
  • In
  • the US, where Dupixin is the leading biologic in eight of its nine approved FDA approved i…
  • as disclosed by Sonofi. ALIA HD quarterly net sales in the U.S. reached a new all-time hig…
  • 20% sequentially, reflecting the value retinal specialists and their patients see in exten…
  • syringe before the end of the year, and we expect it to drive even further adoption if app…
  • melanoma skin cancers and the second most prescribed immunotherapy in non-small cell lung …
  • $400 million. Last week at ESMO, we presented longer-term data from our phase three C POST…

Libtio is now on an annual run rate of approximately $2.2 billion and remains the foundation for our broader oncology strategy. Beyond our strong commercial execution, our pipeline is poised to deliver several potential blockbuster opportunities over the next several years. Let me highlight new advances in four of our pipeline programs while George will discuss in more detail along with other late-stage clinical programs, including factor 11, linosiphic, and olorepitide.

In neuromuscular disease, we expect an FDA decision in November for SIMDysceran in generalized myastenia gravit.

Passages & reports (2)
  • Libtio is now on an annual run rate of approximately $2.2 billion and remains the foundati…
  • advances in four of our pipeline programs while George will discuss in more detail along w…

If approved, SIDISRAN would be the first SIRNA therapy for generalized myastenia gravitus and the only treatment that can offer quarterly subcutaneous dosing. Early in my career as a neurologist, I cared for many patients with this difficult-to-treat condition, so it is particularly gratifying to see us bring forward a potential new treatment option for them. ?In metabolic disease, MASH affects millions of people and treatment options are limited.

Our side B program is a great example of our genetics-driven scientific process. Regeneral and Genetics Center discovered that people with naturally occurring loss of function variants of the Side B gene
have a markedly lower risk of fatty liver disease and cirrhosis, which led us to develop a first-in-class sRNA that targets side B. We are encouraged by the initial clinical data, which suggests best-in-class best in disease potential, and we are rapidly advancing this program into registration-enabling studies.

I'd also like to highlight our program for postural orthostatic tachycardia syndrome, or POTS. This is an increasingly recognized debilitating condition that affects many young people, often disrupting school, work, and
daily life with very few effective treatment options and no FDA approved medicines. Recent estimates suggest that between 500,000 and several million people in the U.S. alone suffer from POS. We believe the initial clinical data that George will highlight supports our antibodies' potential to become the first FDA approved treatment for this disease.

And we plan to initiate a potentially pivotal study next year pending regulatory feedback. In oncology, we recently shared encouraging data
?for the Uber Matimab, our MOC 16 by CD3 bi-specific antibody, and advanced low grade serious ovarian carcinoma. This is a rare and difficult to treat form of ovarian cancer that often affects younger women who urgently need better treatment options. We saw durable responses in heavily pretreated patients at rates well above those historically seen with available therapies.

We are already enrolling a dedicated potentially registrational cohort and plan to start a confirmatory phase three study next year. Each of these programs is supported by
compelling clinical data, human genetic validation, or both. It is no accident that they span four distinct therapeutic areas and that each has first in class or best in disease potential. That reflects our disease agnostic enterprise approach to RD.

Passages & reports (12)
  • If approved, SIDISRAN would be the first SIRNA therapy for generalized myastenia gravitus …
  • bring forward a potential new treatment option for them.
  • In
  • metabolic disease, MASH affects millions of people and treatment options are limited. Our …
  • have a markedly lower risk of fatty liver disease and cirrhosis, which led us to develop a…
  • registration-enabling studies. I'd also like to highlight our program for postural orthost…
  • daily life with very few effective treatment options and no FDA approved medicines. Recent…
  • potential to become the first FDA approved treatment for this disease. And we plan to init…
  • for
  • the Uber Matimab, our MOC 16 by CD3 bi-specific antibody, and advanced low grade serious o…
  • durable responses in heavily pretreated patients at rates well above those historically se…
  • compelling clinical data, human genetic validation, or both. It is no accident that they s…

Rather than confining ourselves to a few therapeutic areas, we apply our core technologies wherever the science leads us. These technology platforms, including our velocimune antibody, and biospecific engines, regeneral genetics center, and sRNA and gene editing technologies that allow us to translate genetic discoveries like SIDE B into potential medicines. Today, that approach supports approximately 50 clinical programs spanning immunology, oncology, ophthalmology, hematology, cardiovascular and metabolic diseases, neurology, and rare diseases.

Our
commercial organization has been built the same way. Our teams already call on ophthalmologists, dermatologists, pulmonologists, allergists, gastroenterologists, ENT specialists, oncologists, cardiologists, and hematologists. And if SEMDysceran is approved, we will begin to call on neurologists as ?well. That means many of our pipeline medicines, including several of the programs I just mentioned, can launch into specialties where we already ?have deep relationships and expertise and can leverage our existing infrastructure and capabilities.

Briefly on business development. Historically, we have been a net outlicensor of innovation, with the most recent example being the expansion of our alliance with SNOFI.
We are contributing to the alliance four next generation long acting antibodies, all invented at Regeneron, that target the same pathways that made Dubixon so successful. Regeneron will lead research and development, ?and SNOFI will lead global commercialization now with greater transparency and increased participation by Regeneron.

If approved, these medicines can also benefit
?from DePix's commercial leadership and the strong market access position it has established, an advantage neither company could capture on its ?own. At the same time, our financial strength positions us to bring differentiated external innovation into Regeneron. We have done this effectively to date, primarily through early stage research collaborations, including those that built our emerging genetic medicines pipeline across sRNA therapeutics, gene therapy, and gene editing. ?

We
continue to evaluate a wide range of opportunities from early clinical programs and platforms to commercial stage products with a sharp focus on valuation and strategic fit. In closing, this was an exceptional quarter by every measure. Our three core growth brands are performing at record levels, and our expanded alliance with Sanafi positions us to leave the next era of type 2 inflammation medicines.

Our pipeline is poised to deliver additional potential blockbusters across a broad range of diseases, and our commercial
organization is built to bring them to patients. Our future is bright, and we remain focused on translating our science into new medicines that can make a meaningful difference for patients and create long term value for shareholders. With that, let me turn the call over to George.

Thanks,
Len.

Passages & reports (20)
  • Rather than confining ourselves to a few therapeutic areas, we apply our core technologies…
  • discoveries like SIDE B into potential medicines. Today, that approach supports approximat…
  • commercial organization has been built the same way. Our teams already call on ophthalmolo…
  • well.
  • That means many of our pipeline medicines, including several of the programs I just mentio…
  • have
  • deep relationships and expertise and can leverage our existing infrastructure and capabili…
  • We are contributing to the alliance four next generation long acting antibodies, all inven…
  • and
  • SNOFI will lead global commercialization now with greater transparency and increased parti…
  • from
  • DePix's commercial leadership and the strong market access position it has established, an…
  • own.
  • At the same time, our financial strength positions us to bring differentiated external inn…
  • gene editing.
  • We
  • continue to evaluate a wide range of opportunities from early clinical programs and platfo…
  • three core growth brands are performing at record levels, and our expanded alliance with S…
  • organization is built to bring them to patients. Our future is bright, and we remain focus…
  • Len.

Speaker 1

For my remarks today, I'll first provide further details on the four programs that Len highlighted, then cover other key updates from our pipeline. Beginning with our C5 program, regulatory submissions are under review for some discerin, our C5 sRNA for generalized myocenia gravis or GMG. An FDA decision is expected next month, and a European Commission decision is anticipated in the second half of 2027.

Passages & reports (2)
  • For my remarks today, I'll first provide further details on the four programs that Len hig…
  • or GMG. An FDA decision is expected next month, and a European Commission decision is anti…

Speaker unclear

?If

Passages & reports (1)
  • If

Speaker 2

approved, some discerin would be the first and only SIRNA therapy approved for GMG. It would be distinguished

Passages & reports (1)
  • approved, some discerin would be the first and only SIRNA therapy approved for GMG. It wou…

Speaker unclear

?by a combination

Passages & reports (1)
  • by a combination

Speaker 1

of rapid onset, consistent efficacy throughout the dosing interval, manageable safety, and convenient subcutaneous ?dosing just four times per year. Our C5 program also includes a coformulation of ?some giserin with Pozelam, our ?C5 antibody that's already FDA approved for ?protein losing enteropathy. Together, they are being evaluated as a combination

Passages & reports (9)
  • of rapid onset, consistent efficacy throughout the dosing interval, manageable safety, and…
  • dosing
  • just four times per year. Our C5 program also includes a coformulation of
  • some giserin with
  • Pozelam, our
  • C5
  • antibody that's already FDA approved for
  • protein losing enteropathy.
  • Together, they are being evaluated as a combination

Speaker unclear

?therapy for paroxysmal noturnal

Passages & reports (1)
  • therapy for paroxysmal noturnal

Speaker 1

hemoglobin urea or PNH, where ?we expect ?to report pivotal results by the end of the year. Initial results from a lead-in cohort of the phase three trial suggest that our novel combination approach could provide best-in-class control of intravascular hemolysis. Our C5 program further includes evaluating some discerin with and without Pazellam in geographic atrophy or GA via systemic administration. We now expect to report interim 26-week data from an exploratory cohort of our ongoing phase two-three study in early 2027, where we hope ?to see a trend towards slowing of lesion growth comparable to the approved agents at a similar time point.

A potential advantage
?of our systemic approach is the ability to treat bilateral disease, which

Passages & reports (10)
  • hemoglobin urea or PNH, where
  • we
  • expect
  • to report
  • pivotal results by the end of the year. Initial results from a lead-in cohort of the phase…
  • in geographic atrophy or GA via systemic administration. We now expect to report interim 2…
  • to see a
  • trend towards slowing of lesion growth comparable to the approved agents at a similar time…
  • of our
  • systemic approach is the ability to treat bilateral disease, which

Speaker 2

affects many patients, while avoiding

Passages & reports (1)
  • affects many patients, while avoiding

Speaker unclear

?the potentially devastating ocular safety events seen with certain FDA-approved agents that are delivered

Passages & reports (1)
  • the potentially devastating ocular safety events seen with certain FDA-approved agents tha…

Speaker 1

intravitreally.

Passages & reports (1)
  • intravitreally.

Speaker unclear

?In addition, we are

Passages & reports (1)
  • In addition, we are

Speaker 3

Unverified voice label

exploring our own intravitrial administration

Passages & reports (1)
  • exploring our own intravitrial administration

Speaker unclear

?of

Passages & reports (1)
  • of

Speaker 1

Faziloman, which might also offer

Passages & reports (1)
  • Faziloman, which might also offer

Speaker 3

safety advantage over

Passages & reports (1)
  • safety advantage over

Speaker unclear

?currently

Passages & reports (1)
  • currently

Speaker 1

approved therapies. Moving to MASH, at the upcoming liver meeting in November, we will present first in human data for our SIRNA for PSI B. This target was discovered by our Regeneron Genetics Center, which identified SIDE B's

Passages & reports (1)
  • approved therapies. Moving to MASH, at the upcoming liver meeting in November, we will pre…

Speaker unclear

?unprecedented

Passages & reports (1)
  • unprecedented

Speaker 3

ability to

Passages & reports (1)
  • ability to

Speaker 1

protect against liver fat

Passages & reports (1)
  • protect against liver fat

Speaker unclear

?and liver

Passages & reports (1)
  • and liver

Speaker 3

disease through

Passages & reports (1)
  • disease through

Speaker unclear

?our large scale human genetics database. In the initial data from 40 participants,

Passages & reports (1)
  • our large scale human genetics database. In the initial data from 40 participants,

Speaker 3

a single dose was well tolerated and reduced liver fat by approximately 70% on average from baseline in just two weeks, 12 weeks,

Passages & reports (1)
  • a single dose was well tolerated and reduced liver fat by approximately 70% on average fro…

Speaker unclear

?bringing mean liver fat to near or below upper limit of

Passages & reports (1)
  • bringing mean liver fat to near or below upper limit of

Speaker 3

normal at every dose level tested. This effect was durable through 24 weeks of follow-up and was accompanied by improvements in liver enzymes consistent with reduced liver cell injury. These results not only clinically validate the side beef

Passages & reports (1)
  • normal at every dose level tested. This effect was durable through 24 weeks of follow-up a…

Speaker 1

discovery from the Regeneron Genetic Center, but

Passages & reports (1)
  • discovery from the Regeneron Genetic Center, but

Speaker unclear

?suggest that

Passages & reports (1)
  • suggest that

Speaker 3

we ?have a breakthrough new approach that directly addresses a genetic driver of MASH and could benefit the millions of MASH patients underserved by current approaches. We are working to rapidly advance to registrational trials and look forward to sharing more about this agent ?at our next Regeneron Roundtable Investor event scheduled for November 10th. Moving to postural orthostatic tachycardia syndrome or POTS. This disease appears to be driven by chronic pathological depletion of intravascular volume.

Current treatments include salt and
fluid administration, which provide only short term relief. There are no FDA approved therapies, and off label treatments are generally unsatisfactory. At the American Autonomic Society Congress in November, we will be reporting results, initial results from our phase two study. After a single treatment with high dose Bellan Sivart, we saw improvements in the two key endpoints for this disease: tachycardia and orthostatic symptoms, sustained over four weeks from a single dose.

These improvements appear to be associated with durable
restoration of intravascular volume. We are planning to initiate a potentially registrational study in the first half of next year, pending regulatory feedback, and we believe this could be a game-changing treatment for a debilitating disease with significant unmet need. Next, turning to Ubomatomab, our MUC-16 by C3 bi-specific antibody in development for ovarian cancer, which was featured in a late-breaking plenary session at the International Gynecological Cancer Society meeting.

The data presented there, along with additional data, indicate that Ubomatimab monotherapy has an approximately 70%
objective response rate with prolonged progression-free survival in women with advanced low-grade serious ovarian cancer, with an acceptable safety profile and no biomarker selection required. To put this in context, chemotherapy and endocrine therapy have historically delivered response rates below 15% in this setting, and the only approved therapy achieved a 44% response rate, but only in the roughly 30% of patients ?with low grade serious ovarian cancers whose tumor carry a specific biomarker.

Based on these encouraging early results for UBAMATIMAMAB, we're enrolling a potentially registrational cohort and plan to start a confirmatory phase three trial in mid-2027. Turning now to our larger late-stage programs and
starting with LinoZipic, our BCMA by C3 Bispecific. ?We believe LinoZiphic is differentiated not only by the efficacy demonstrated in late-line multiple myeloma, but also by our development strategy, which creates important new opportunities in first and second-line settings and even in pre-malignant disease, with pivotal readouts beginning next year.

In
2027, we expect initial results from our confirmatory trial of linosipic monotherapy versus standard of care in patients with multiple myeloma who have received at least one prior line of therapy. In 2028, we expect initial results from our first line study in transplant inalgebral patients as well as from our linosipic carfilzomib combination study in patients who have received at least one prior line of therapy.

We are also enrolling potentially registrational cohort in second line light chain amyloidosis and plan to start a phase three study in first-line light chain amyloidosis by early 2027. In addition, we're
actively enrolling a phase three trial in high-risk smoldering myeloma. We have also we also have a differentiated development strategy for OGNexdoman, our C20 by C D3 Bispecific. We have a regulatory application under FDA review for relapse refractory diffuse large B cell lymphoma with a February 2027 target action date.

Importantly, we expect results in 2028 from our fully enrolled phase three study of OG-nexomab monotherapy in first-line follicular enfoam, which could provide these patients who have high unmet need with the first bispecific and chemo-free
immunotherapy option. Moving to anticoagulation. For factor 11 inhibition, we continue to favor our antibody approach over small molecules because antibodies may enable more potent and specific inhibition with the potential to improve antithrombotic activity without increasing bleeding risk or introducing off-target safety issues.

Our program features Synvasibar, our catalytic domain antibody, and MRESIBART,
?our AT domain antibody. I'm pleased to report that all but one of the planned phase three studies are now enrolling patients. These studies span venous thromboembolism prevention after total knee replacement, stroke prevention in patients with atrial fibrillation, cancer associated thrombosis, peripheral artery disease, and most recently venous thromboembolism prevention in patients with peripherally inserted central catheters.

The one remaining phase three study yet to initiate in secondary stroke prevention is expected to begin enrollment by year end. We expect pivotal results from our knee replacement program starting next year, with other pivotal studies expected to read out in
2028 and beyond. Turning to allotareptide, our dual GLP1 GIF receptor agonist in license from HANSO. Recently, HANSO presented encouraging efficacy, safety, and tolerability data from their phase three trial in patients with obesity in China at the European Association for the Study of Diabetes Conference.

We look forward to starting our global phase three program, which is differentiated by our ability to coformulate oloreptide with pralluent, our PCSK9 antibody. We believe this could provide an important new treatment option for the many patients with obesity and type 2 diabetes who comorbidally also suffer
from hypercholesterolemia and increased cardiovascular risk. And we plan to begin registrational studies of this combination next year. ?

As
Len discussed, we recently announced an expansion of our alliance with Sanafi. Building on the success of Dupixin and the validation of the IL4 and IL13 pathways as symptom drivers of type 2 inflammation, the alliance is advancing with generons for fully human, velocimine derived, long acting antibodies and biospecifics. These candidates are designed to preserve dupixant like efficacy and safety while enabling substantially less frequent dosing.

All four candidates avoid the heavy engineering that tends to compromise biopharmaceutical properties or raise the risk of anti drug antibodies. Our candidates, which are
fully human and non engineered, also share important molecular properties, so learnings from one should carry over to the others and potentially support an expedited development. Our first inhuman trial for our LEED IL-13 antibody, which has a target dosing interval of every three to six months, is currently enrolling with patients with atopic dermatitis, with registrational trials expected ?to begin in late 2027 and 2028.

Three additional programs
?are long acting IL 413 Bispecific, a long acting antibody to IL4 receptor alpha, and an IL-4 ligand antibody are expected to enter the clinic next year. Relevant to these programs, I want to remind I want to end by reminding ?you that we have previously shared early clinical results for our BCMA by C D3 bispecific in combination with dupixin in severe food allergy.

These results strongly supported our hypothesis that food allergies could potentially be cured by rapidly and completely depleting plasma cells, which produce
immunoglobulins, including including the allergy causing IgEs, and then continuously suppressing the return of IgE antibodies by blocking IL4 and IL13. While the BCMA by CD3 eliminates plasma cells producing all classes of immunoglobulins, we have invented a new biospecific antibody that selectively eliminates only the IgE producing and allergy causing plasma cells.

We plan to build on our groundbreaking results combining our BCMA biospecific with dupixin by expeditiously pursuing this more targeted approach with clinical studies of this new
biospecific antibodies to start in the first half of 2027. In summary, we have strong momentum across our broad and diverse pipeline that we believe that has the potential to change the practice of medicine across many diseases with high unmet need.

With that, let me turn it over to Marion.

Passages & reports (42)
  • we
  • have
  • a breakthrough new approach that directly addresses a genetic driver of MASH and could ben…
  • at
  • our next Regeneron Roundtable Investor event scheduled for November 10th. Moving to postur…
  • fluid administration, which provide only short term relief. There are no FDA approved ther…
  • initial results from our phase two study. After a single treatment with high dose Bellan S…
  • restoration of intravascular volume. We are planning to initiate a potentially registratio…
  • C3 bi-specific antibody in development for ovarian cancer, which was featured in a late-br…
  • objective response rate with prolonged progression-free survival in women with advanced lo…
  • setting, and the only approved therapy achieved a 44% response rate, but only in the rough…
  • with
  • low grade serious ovarian cancers whose tumor carry a specific biomarker. Based on these e…
  • starting with LinoZipic, our BCMA by C3 Bispecific.
  • We
  • believe LinoZiphic is differentiated not only by the efficacy demonstrated in late-line mu…
  • 2027, we expect initial results from our confirmatory trial of linosipic monotherapy versu…
  • carfilzomib combination study in patients who have received at least one prior line of the…
  • actively enrolling a phase three trial in high-risk smoldering myeloma. We have also we al…
  • 2027 target action date. Importantly, we expect results in 2028 from our fully enrolled ph…
  • immunotherapy option. Moving to anticoagulation. For factor 11 inhibition, we continue to …
  • introducing off-target safety issues. Our program features Synvasibar, our catalytic domai…
  • our
  • AT domain antibody. I'm pleased to report that all but one of the planned phase three stud…
  • venous thromboembolism prevention in patients with peripherally inserted central catheters…
  • 2028 and beyond. Turning to allotareptide, our dual GLP1 GIF receptor agonist in license f…
  • Conference. We look forward to starting our global phase three program, which is different…
  • from hypercholesterolemia and increased cardiovascular risk. And we plan to begin registra…
  • As
  • Len discussed, we recently announced an expansion of our alliance with Sanafi. Building on…
  • and biospecifics. These candidates are designed to preserve dupixant like efficacy and saf…
  • fully human and non engineered, also share important molecular properties, so learnings fr…
  • atopic dermatitis, with registrational trials expected
  • to
  • begin in late 2027 and 2028. Three additional programs
  • are
  • long acting IL 413 Bispecific, a long acting antibody to IL4 receptor alpha, and an IL-4 l…
  • you
  • that we have previously shared early clinical results for our BCMA by C D3 bispecific in c…
  • immunoglobulins, including including the allergy causing IgEs, and then continuously suppr…
  • biospecific antibody that selectively eliminates only the IgE producing and allergy causin…
  • biospecific antibodies to start in the first half of 2027. In summary, we have strong mome…

Speaker 4

Unverified voice label

Thank you, George. Our third quarter results reflect strong commercial execution across our portfolio, with our largest brands achieving new all-time highs in net sales. Our team is also focused on recent and upcoming launches, with PASITRU now approved in the U.S. for ultra-rare FOP, and we are preparing for the November PADUFA for some discerin in generalized myocemia gravis, starting with depixant, which continues to deliver transformative benefits to patients across nine type two inflammatory diseases, with more than one point five million patients currently treated worldwide.

In the U.S., depixant remains the most prescribed branded biologic among dermatologists,
pulmonologists, allergists, and ENTs. Third quarter worldwide net sales exceeded 6.5 billion, reflecting 35% growth on a constant currency basis. U.S. net sales grew 40% year over year to $5.1 billion, driven by continued growth across all indications and age groups, as well as favorable gross to net adjustments as reported by Sanafe.

Dupixin is the leading biologic across our blockbuster indications of atopic dermatitis, asthma, nasal polyps,
?and the synophilic esophagitis, reported by its best in class clinical efficacy and safety profile. Uptake is also strong in our more recently launched indications of COPD, paragonagularis, chronic spontaneous articaria, bolus pemphylloid, and allergic fungal rhinocitis, with continued growth in neuter brand prescriptions. With significant opportunity for future growth across all nine indications, DePixin is well positioned over both the near and long term.

Additionally, we are excited about the recently announced expansion of the Regeneral and Sanafi Alliance and to continue building on the strong foundation we've laid together with DePixin. Turning to our retinal franchise, in the
third quarter combined ILEAHD and ILEA US net sales were $1.1 billion, down 1% compared to last year, with ILEAHD now comprising nearly two thirds of the franchise net sales.

Third quarter IEHD net sales in the U.S. were $699 million,
up 62% versus prior year. These results demonstrate strong physician unit demand, which grew 20% from the second quarter. This growth is driven by the ongoing benefit of recent label enhancements, which have increased adoption and broadened use of ILEHD across the spectrum of retinal practices.

Passages & reports (9)
  • Thank you, George. Our third quarter results reflect strong commercial execution across ou…
  • discerin in generalized myocemia gravis, starting with depixant, which continues to delive…
  • pulmonologists, allergists, and ENTs. Third quarter worldwide net sales exceeded 6.5 billi…
  • as favorable gross to net adjustments as reported by Sanafe. Dupixin is the leading biolog…
  • and the
  • synophilic esophagitis, reported by its best in class clinical efficacy and safety profile…
  • significant opportunity for future growth across all nine indications, DePixin is well pos…
  • third quarter combined ILEAHD and ILEA US net sales were $1.1 billion, down 1% compared to…
  • up 62% versus prior year. These results demonstrate strong physician unit demand, which gr…

Physicians increasingly recognize IEHD as the best in class product in the anti-VEGF category based on its efficacy, safety, and durability. ILEA U.S. net sales were $400 million for the quarter, a 41% decrease versus the prior year. Sequential physician unit demand declined by a high single digit percentage compared to the second quarter, with this decline partially offset by favorable gross to net adjustments.

Both ILEHD and ILEA benefited modestly from the timing of end-of-quarter shipments. Looking ahead to the fourth quarter, we expect continued ILEA
HD momentum with sequential physician unit demand growth of approximately 10%, partially offset by ongoing pricing pressure, resulting in full year net sales growth of over 50% compared with 2025. For ILEA, we expect a sequential demand decline in the low to mid teens in the fourth quarter.

Overall, the franchise remains in a strong position despite increasing competition from additional flibercep 2 milligram biosimilar launches, and we look forward to potential FDA approval of the ILEA HD prefilled syringe to help sustain ILEAHD momentum in 2027 and beyond.

Passages & reports (4)
  • Physicians increasingly recognize IEHD as the best in class product in the anti-VEGF categ…
  • declined by a high single digit percentage compared to the second quarter, with this decli…
  • HD momentum with sequential physician unit demand growth of approximately 10%, partially o…
  • fourth quarter. Overall, the franchise remains in a strong position despite increasing com…

Turning to Lib Tia, which delivered worldwide net sales of 550 million, up 51% year over year on a constant currency basis. And the U.S. net sales were $396 million up 81%. In non melanoma skin cancer, Lobtail continues its strong trajectory as the leading immunotherapy. ?In the U.S., the recent approval in adjuvant CSE is helping to drive growth and is changing the treatment paradigm.

Lobtio remains the only NCCN category one preferred immunotherapy option for eligible patients, and ongoing formulary wins are driving increased usage. In non-small cell lung cancer, Libio remains the second most
prescribed immunotherapy as physicians increasingly recognize its strong clinical profile. We continue to build on leptio's strong momentum by enhancing the patient experience through extended dosing and shorter infusion times across all approved indications.

We recently received a positive CHMP opinion for every six week dosing for Libio,
along with an infusion time as short as 15 minutes. An SBLA for this updated dosing regimen is under review with the FDA with a decision expected by March 2027. We expect continued growth for LibTio as we gain incremental share in lung cancer and drive uptake and adjuvant CSCC. Onto Lenozyfic and multiple myeloma, physician feedback on the currently approved late-line setting remains positive ?based on LenoZic's differentiated efficacy and safety profiles, lower hospitalization requirements, and convenient dosing.

Despite its strong profile, we expect LenoZiphic growth to remain modest as we work to advance into earlier lines of therapy. We are also building regenerance rare disease Portfolio serving patients with
significant unmet need. FKISA continues to grow in its sixth year on the market with U.S. net sales of 55 million, up 28% versus the prior year. We have also expanded our portfolio with the recent launches of Wetharmony for genetic hearing loss and Passenger for FOP.

Initial progress for both brands is promising, and
we look forward to helping patients suffering from these devastating diseases. Finally, in neurology, we're preparing for the potential launch of some discerin in generalized myasthenia gravis, which has a November fiduciate. We see significant commercial opportunity for some dyscerin based on three key factors. It's novel SIRNA modality, rapid onset, and durable efficacy without the waning treatment effect observed with many other approved therapies, and convenient four times per year subcutaneous dosing.

In closing, our third quarter results reflect strong commercial capability across therapeutic areas. We've built an effective commercial
infrastructure that enables us to execute across both inline brands and new launches. As Len mentioned earlier, our commercialization platform currently spans nearly every relevant specialty, and this market experience positions as well for the many potential new products from our pipeline. Whether a common or rare disease medicine, specialty or internal medicine prescriber, medical or pharmacy benefit product, we are confident in the capabilities of our commercial organization in both the near and longer term.

And with that, I'll turn over to Chris.

Passages & reports (13)
  • Turning to Lib Tia, which delivered worldwide net sales of 550 million, up 51% year over y…
  • In
  • the U.S., the recent approval in adjuvant CSE is helping to drive growth and is changing t…
  • prescribed immunotherapy as physicians increasingly recognize its strong clinical profile.…
  • along with an infusion time as short as 15 minutes. An SBLA for this updated dosing regime…
  • multiple myeloma, physician feedback on the currently approved late-line setting remains p…
  • based
  • on LenoZic's differentiated efficacy and safety profiles, lower hospitalization requiremen…
  • significant unmet need. FKISA continues to grow in its sixth year on the market with U.S. …
  • we look forward to helping patients suffering from these devastating diseases. Finally, in…
  • SIRNA modality, rapid onset, and durable efficacy without the waning treatment effect obse…
  • infrastructure that enables us to execute across both inline brands and new launches. As L…
  • or rare disease medicine, specialty or internal medicine prescriber, medical or pharmacy b…

Speaker 1

Thank you, Marion. My comments today on Regeneron's financial results and outlook will be on a non-gap basis unless otherwise noted. Regeneron delivered a strong third quarter, once again reaching double-digit growth on both the top and bottom line, driven by some sustained momentum across our key growth drivers and solid execution throughout the business. Third quarter total revenue increased 36% from the prior year to $5.1 billion, driven primarily by higher Sanafi collaboration revenue, along with strong growth from both LibTyo and ILEAHD.

Third quarter, diluted net income per share grew 70% to $20.07

Passages & reports (2)
  • Thank you, Marion. My comments today on Regeneron's financial results and outlook will be …
  • business. Third quarter total revenue increased 36% from the prior year to $5.1 billion, d…

Speaker unclear

?on net income of $2.2 billion.

Passages & reports (1)
  • on net income of $2.2 billion.

Speaker 3

Beginning with the Sanafi collaboration, third quarter collaboration revenues reached an

Passages & reports (1)
  • Beginning with the Sanafi collaboration, third quarter collaboration revenues reached an

Speaker 1

all-time high

Passages & reports (1)
  • all-time high

Speaker 3

of $2.7

Passages & reports (1)
  • of $2.7

Speaker 1

billion, including

Passages & reports (1)
  • billion, including

Speaker 3

$2.6 billion from our share of collaboration profits. Our share of profits increased 77% versus the prior year, primarily

Passages & reports (1)
  • $2.6 billion from our share of collaboration profits. Our share of profits increased 77% v…

Speaker unclear

?driven by continued depixant net sales growth and the repayment of the Sanafi development

Passages & reports (1)
  • driven by continued depixant net sales growth and the repayment of the Sanafi development

Speaker 5

Unverified voice label

balance,

Passages & reports (1)
  • balance,

Speaker unclear

?which was completed in the second quarter.

Passages & reports (1)
  • which was completed in the second quarter.

Speaker 5

Consequently, in the ?third quarter, we recorded our full share of collaboration profits for the first ?time. Under the recently amended antibody collaboration, Regeneron and Sanafi will share equally the development and commercialization costs of four next generation antibodies. Since RD costs will be co co-funded as they are incurred, there will be no RD development balance. Global profits from these antibodies

Passages & reports (5)
  • Consequently, in the
  • third
  • quarter, we recorded our full share of collaboration profits for the first
  • time.
  • Under the recently amended antibody collaboration, Regeneron and Sanafi will share equally…

Speaker unclear

?will also be shared 50-50 while the existing economic terms

Passages & reports (1)
  • will also be shared 50-50 while the existing economic terms

Speaker 5

for Depixant and Kevzara remain unchanged. Regeneron expects to record the full $1 billion upfront payment as Sanafi Collaboration Revenue in the fourth quarter with any future milestone payments recognized in full in the period achieved.

Passages & reports (1)
  • for Depixant and Kevzara remain unchanged. Regeneron expects to record the full $1 billion…

Speaker unclear

?Moving the buyer. Third quarter net sales of ILEA 8 MIG

Passages & reports (1)
  • Moving the buyer. Third quarter net sales of ILEA 8 MIG

Speaker 1

and

Passages & reports (1)
  • and

Speaker unclear

?ILEA outside the U.S. were $643 million,

Passages & reports (1)
  • ILEA outside the U.S. were $643 million,

Speaker 5

inclusive of $384 million of ILEA

Passages & reports (1)
  • inclusive of $384 million of ILEA

Speaker unclear

?8 MiG sales. Total buyer collaboration revenue was

Passages & reports (1)
  • 8 MiG sales. Total buyer collaboration revenue was

Speaker 5

$267 million, of which

Passages & reports (1)
  • $267 million, of which

Speaker unclear

?$212 million related to our share of net profits outside the U.S. Other

Passages & reports (1)
  • $212 million related to our share of net profits outside the U.S. Other

Speaker 5

revenues

Passages & reports (1)
  • revenues

Speaker unclear

?in the third quarter increased

Passages & reports (1)
  • in the third quarter increased

Speaker 5

57% year ?over year to $310 million, including $253 million from our share of Arcalis profits and Alaris royalties. Third quarter Ilaris

Passages & reports (3)
  • 57% year
  • over
  • year to $310 million, including $253 million from our share of Arcalis profits and Alaris …

Speaker unclear

?royalty revenue included an approximately

Passages & reports (1)
  • royalty revenue included an approximately

Speaker 5

$60 million cumulative catch up adjustment, reflecting the application of the highest royalty tier on year to date sales. This cumulative catch up will not recur in the fourth quarter. Now to our operating expenses. Third quarter RD ?expense was $1.7 billion, driven by continued advancement ?of our broad clinical pipeline as well as the timing of related clinical manufacturing. Third quarter SGA was $588 million, an increase of 9% year over year, reflecting investments across our commercial organization

Passages & reports (5)
  • $60 million cumulative catch up adjustment, reflecting the application of the highest roya…
  • expense
  • was $1.7 billion, driven by continued advancement
  • of our
  • broad clinical pipeline as well as the timing of related clinical manufacturing. Third qua…

Speaker unclear

?and broader business. Our third quarter effective tax

Passages & reports (1)
  • and broader business. Our third quarter effective tax

Speaker 5

rate was 15%. The

Passages & reports (1)
  • rate was 15%. The

Speaker unclear

?year-over-year increase was primarily due to a shift in the geographic mix of

Passages & reports (1)
  • year-over-year increase was primarily due to a shift in the geographic mix of

Speaker 5

our pre-tax income driven by higher Sanafi ?collaboration revenue. Regeneron ?generated $2.9 billion of free cash flow through the first

Passages & reports (5)
  • our pre-tax income driven by higher Sanafi
  • collaboration revenue.
  • Regeneron
  • generated
  • $2.9 billion of free cash flow through the first

Speaker unclear

?nine months of 2026 and ended the quarter with

Passages & reports (1)
  • nine months of 2026 and ended the quarter with

Speaker 5

$16.2 billion of cash and marketable securities net of debt. In the first nine months of 2026, we deployed nearly $3 billion across share repurchases, business development, and dividends. This included $2.3 billion to repurchase $3.2 million shares. We expect full-year share repurchases to total approximately $3 billion, and as of September 30th, we had $2.2 billion remaining under our repurchase authorization. Moving

Passages & reports (2)
  • $16.2 billion of cash and marketable securities net of debt. In the first nine months of 2…
  • full-year share repurchases to total approximately $3 billion, and as of September 30th, w…

Speaker unclear

?to guidance, we made modest

Passages & reports (1)
  • to guidance, we made modest

Speaker 5

refinements to ?our 2026 financial guidance as we enter the last quarter of the year. A full summary of our guidance can be found in our earnings press release published earlier this morning. As we look to 2027, Len and George discussed the meaningful progress we are making across our innovative pipeline. We expect to advance multiple large registrational programs in myeloma, ?anti coagulation, obesity, and emerging mid stage opportunities with significant revenue potential, such as our programs in POTS and MESH. ?

This
year alone, we are on pace to initiate more than 15 phase three trials. We believe these investments can create substantial long term value. To support this progress, we currently expect 2027 RD expense to increase by a mid teens percentage compared with 2026. Regarding

Passages & reports (8)
  • refinements to
  • our 2026 financial
  • guidance as we enter the last quarter of the year. A full summary of our guidance can be f…
  • in myeloma,
  • anti
  • coagulation, obesity, and emerging mid stage opportunities with significant revenue potent…
  • This
  • year alone, we are on pace to initiate more than 15 phase three trials. We believe these i…

Speaker unclear

?our 2027 effective tax rate, we expect approximately 100 to 200 basis points of upward pressure relative to 2026, consistent consistent with

Passages & reports (1)
  • our 2027 effective tax rate, we expect approximately 100 to 200 basis points of upward pre…

Speaker 5

our prior long term tax ?rate commentary. Finally, turning to the new Bardo agreement for NMAZEB, beginning in late 2027, we expect to supply additional treatment doses to the U.S. government through 2031. Therefore, we do not anticipate recording any revenue in the fourth quarter of 2026 for NMAZEB. In conclusion, we delivered another outstanding quarter and remain well positioned to invest in our differentiated pipeline, deliver important

Passages & reports (4)
  • our prior long term tax
  • rate commentary.
  • Finally, turning to the new Bardo agreement for NMAZEB, beginning in late 2027, we expect …
  • positioned to invest in our differentiated pipeline, deliver important

Speaker 2

medicines to patients, and create durable

Passages & reports (1)
  • medicines to patients, and create durable

Speaker unclear

?long-term value value for shareholders. With that, I'll pass the call back to Ryan.

Passages & reports (1)
  • long-term value value for shareholders. With that, I'll pass the call back to Ryan.

Speaker 1

Chris, this concludes our prepared remarks. We will now open up the call for QA. ?To ensure we are able to address as many questions as possible, we will answer one question from each caller before moving to the next. Shannon, can we please go to our first question?

Passages & reports (3)
  • Chris, this concludes our prepared remarks. We will now open up the call for QA.
  • To
  • ensure we are able to address as many questions as possible, we will answer one question f…

Questions & answers

Speaker 0

Thank you. To ask the question, please press star one one of your telephone and wait for your name to be announced. To withdraw your question, please press star one one again. Our first question comes from the line of Salvine Ricker with Goldman Sachs. Your line is now open.

Passages & reports (1)
  • Thank you. To ask the question, please press star one one of your telephone and wait for y…

Speaker unclear

?Hey, good

Passages & reports (1)
  • Hey, good

Speaker 5

morning. Thank you for taking our question. This is Elizabeth Webster on for Salvine. Just ahead of AASLD, could you further frame the clinical data from side B we've seen to date in the context of the competitive landscape and expand upon where Regeneron would position this asset? And in your view, what are the key aspects of differentiation? Also noting you will speak about this at the round table, but any color you can share now would be appreciated.

Thank

Passages & reports (2)
  • morning. Thank you for taking our question. This is Elizabeth Webster on for Salvine. Just…
  • key aspects of differentiation? Also noting you will speak about this at the round table, …

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 3

Well, the other approaches to MASH and reducing liver fat are all somewhat indirect in that they are not directly addressing the fundamental genetic pathway that's underlying or driving this disease. They work, for example, by trying to decrease body weight, for example, some

Passages & reports (2)
  • Well, the other approaches to MASH and reducing liver fat are all somewhat indirect in tha…
  • to decrease body weight, for example, some

Speaker 1

glutide or GLP, which lowers body weight, which then indirectly lowers liver fat. Similarly,

Passages & reports (1)
  • glutide or GLP, which lowers body weight, which then indirectly lowers liver fat. Similarl…

Speaker 3

the product from Madrigal works by a separate mechanism as ?well. This is the first pathway that directly involves a genetically validated target that is central to protecting the liver against multiple liver diseases, including liver fat generated diseases. Reflecting the genetics and the specificity and importance of this pathway, the liver fat reductions that one is seeing here are unprecedented in the rapidity of onset and the depth of the liver fat reductions.

As we said, they're on the order of 70% achieved in just a few weeks.

Passages & reports (4)
  • the product from Madrigal works by a separate mechanism as
  • well.
  • This is the first pathway that directly involves a genetically validated target that is ce…
  • specificity and importance of this pathway, the liver fat reductions that one is seeing he…

And this is with a uh a single dose lasting for a very long period of time. These are really game-changing results and of course highly supported with the genetics. So, of course, we've reproduced now the genetic effects on liver fat. This gives us even more confidence that we're going to reproduce the genetic effects on benefits in terms of liver disease. So this is really game changing, unprecedented.

There's nothing like this before for this disease. And I think it's reflective of our approach to using large scale human
genetics to actually define the underlying mechanism of disease and not just come up with drugs that sort of accidentally or by chance also benefit a disease of interest, but actually defining the underlying genetic pathway causing the disease, directly targeting with one of our signature platforms, in this case the SIRNA approach, and producing unprecedented results in these early stage data.

Passages & reports (4)
  • And this is with a uh a single dose lasting for a very long period of time. These are real…
  • going to reproduce the genetic effects on benefits in terms of liver disease. So this is r…
  • genetics to actually define the underlying mechanism of disease and not just come up with …
  • signature platforms, in this case the SIRNA approach, and producing unprecedented results …

Speaker 1

Thanks, George, and we certainly look forward to highlighting that in a couple weeks at our roundtable event on November 10th. Shannon, let's move to the next question, please.

Passages & reports (1)
  • Thanks, George, and we certainly look forward to highlighting that in a couple weeks at ou…

Speaker 0

Our next question comes from the line of Brian Abrahams with RBC Capital Markets. Your line is now open.

Passages & reports (1)
  • Our next question comes from the line of Brian Abrahams with RBC Capital Markets. Your lin…

Speaker 6

Unverified voice label

Hey guys, good morning. Thanks so much for uh for taking up my my question here. ?Wonder if you talk a little bit more about the some Disar and pre-launch activities, just kind of some of the learnings uh there uh as you prepare for the launch. Um, you know, now that you're closer to the approval and a potential label, and and just how you're thinking about the initial uh target audience and uptake.

Thanks.

Passages & reports (4)
  • Hey guys, good morning. Thanks so much for uh for taking up my my question here.
  • Wonder
  • if you talk a little bit more about the some Disar and pre-launch activities, just kind of…
  • audience and uptake. Thanks.

Speaker 4

Sure, very happy to uh to make comments. So we we certainly have a very talented neurology team at Regeneron. Um very pleased with the um caliber experience um that the team has in neurology with other programs and now we're really excited to bring that to Regeneron. The um as we mentioned PADUFA date in November very exciting so launch activities preparation are well underway.

I'm not going to say a lot about launch strategy but delighted to talk about it in the future. But certainly assure everyone that we are launch ready. We look forward to the label and certainly bringing some discerin into the marketplace
as ?a really important enhancement for patients who need this treatment.

Passages & reports (5)
  • Sure, very happy to uh to make comments. So we we certainly have a very talented neurology…
  • PADUFA date in November very exciting so launch activities preparation are well underway. …
  • as
  • a
  • really important enhancement for patients who need this treatment.

Speaker unclear

?Thanks,

Passages & reports (1)
  • Thanks,

Speaker 1

Marion. Let's move to the next question, Shannon.

Passages & reports (1)
  • Marion. Let's move to the next question, Shannon.

Speaker 0

Our next question comes from the line of Akash Tawari with Jeffries. Your line is now open.

Passages & reports (1)
  • Our next question comes from the line of Akash Tawari with Jeffries. Your line is now open…

Speaker 6

Hey, uh thanks so much. I noticed that your Sanifi collaboration allows you to add another early stage Sanafi

Passages & reports (1)
  • Hey, uh thanks so much. I noticed that your Sanifi collaboration allows you to add another…

Speaker 7

Unverified voice label

asset. Um, can we revisit, you know, stat six? If the stat six orals start to deliver efficacy, not better, but let's just say similar to the Pixent, would that be an asset that your team would be interested in adding to the ongoing collaboration with Sanafi? Thank

Passages & reports (1)
  • asset. Um, can we revisit, you know, stat six? If the stat six orals start to deliver effi…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

Yeah, so look, the Alliance is open to uh doing anything and everything that makes sense to build on our expertise.

Passages & reports (1)
  • Yeah, so look, the Alliance is open to uh doing anything and everything that makes sense t…

Speaker 1

Uh I think the oral uh agents are an interesting class, but they're a long way from giving the efficacy and safety uh that to pixin pathway uh blockers would give. Um you're talking of as you further get away

Passages & reports (1)
  • Uh I think the oral uh agents are an interesting class, but they're a long way from giving…

Speaker 2

uh

Passages & reports (1)
  • uh

Speaker 1

from

Passages & reports (1)
  • from

Speaker 2

the membrane and downstream, you always have to deal with other potential uh activities. Uh and frankly, when you get into long uh longer dosing intervals, a daily pill doesn't o afford much of an advantage in convenience, and maybe even have to take it more than once compared to something that you might take once a

Passages & reports (2)
  • the membrane and downstream, you always have to deal with other potential uh activities. U…
  • once a

Speaker 1

quarter or once every six months. So

Passages & reports (1)
  • quarter or once every six months. So

Speaker 2

the

Passages & reports (1)
  • the

Speaker 1

bottom line is

Passages & reports (1)
  • bottom line is

Speaker 2

I ?think uh the alliance uh is open. We have a very good relationship now with Santafi. I think we're back on a very strong track. Um Baylin Garrijo has been really clear cut uh in helping us

Passages & reports (3)
  • I
  • think
  • uh the alliance uh is open. We have a very good relationship now with Santafi. I think we'…

Speaker 1

frame that we want

Passages & reports (1)
  • frame that we want

Speaker 2

to continue to build on depixant uh for a long time.

Passages & reports (1)
  • to continue to build on depixant uh for a long time.

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 1

I think we should add that. Certainly, there may be room for multiple treatment options and and ways at dealing with the patients with so much high unmet need out there. Um but certainly, as Len said, um uh an injectable that can be given, you know, two or four times a year uh will certainly be an incredibly attractive option uh for so many patients.

Whereas, of course, there may also be room for an oral, uh pending, of course, dealing with the efficacy and of course safety issues that Lynn raised. Thank you guys. Uh next question, please, Shannon.

Passages & reports (2)
  • I think we should add that. Certainly, there may be room for multiple treatment options an…
  • year uh will certainly be an incredibly attractive option uh for so many patients. Whereas…

Speaker 0

Our next question comes from the line of Tyler Van Buren with T D Cowan. Your line is now open.

Passages & reports (1)
  • Our next question comes from the line of Tyler Van Buren with T D Cowan. Your line is now …

Speaker unclear

?Hey

Passages & reports (1)
  • Hey

Speaker 3

guys, uh good morning and congratulations on a very, very

Passages & reports (1)
  • guys, uh good morning and congratulations on a very, very

Speaker 1

impressive quarter. Um so is it fair to say that Regeneron will become even more aggressive on the business development front than it was a year ago given the long term new product revenue incentives stretching up to 30 to 40 billion. And what stage of development is the ideal time to acquire external assets in your view? Is it post-phase two so you can have a hand in operating the phase three, or is it post-phase three when you're closer to commercialization?

Passages & reports (2)
  • impressive quarter. Um so is it fair to say that Regeneron will become even more aggressiv…
  • in your view? Is it post-phase two so you can have a hand in operating the phase three, or…

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 1

so Tyler, uh that's a great question. We do appreciate the two

Passages & reports (1)
  • so Tyler, uh that's a great question. We do appreciate the two

Speaker 2

varies in your introductory marks.

Passages & reports (1)
  • varies in your introductory marks.

Speaker 4

I

Passages & reports (1)
  • I

Speaker 2

think our records show you've only given us one very in the past,

Passages & reports (1)
  • think our records show you've only given us one very in the past,

Speaker 1

so thank you for that. Um, in terms of business development, look, we look at the overall spend on investment, if you will, on research and development. And when you add up what other companies spend on external innovation and internal innovation, and what we spend on internal and external innovation, these numbers we're not out of line at all. It's just that we have this

Passages & reports (2)
  • so thank you for that. Um, in terms of business development, look, we look at the overall …
  • external innovation, these numbers we're not out of line at all. It's just that we have th…

Speaker 2

incredibly

Passages & reports (1)
  • incredibly

Speaker 1

productive

Passages & reports (1)
  • productive

Speaker 2

research

Passages & reports (1)
  • research

Speaker 1

effort that George detailed a little

Passages & reports (1)
  • effort that George detailed a little

Speaker unclear

?bit

Passages & reports (1)
  • bit

Speaker 2

that is producing things where some of the things we haven't even

Passages & reports (1)
  • that is producing things where some of the things we haven't even

Speaker 1

talked about and aren't in the clinic yet are still even more exciting than you can imagine. So we are open to any and all

Passages & reports (1)
  • talked about and aren't in the clinic yet are still even more exciting than you can imagin…

Speaker 2

opportunities

Passages & reports (1)
  • opportunities

Speaker 1

at all stages. But as I said in my remarks, we're focused on the science.

Passages & reports (1)
  • at all stages. But as I said in my remarks, we're focused on the science.

Speaker 2

Does it really make sense? We

Passages & reports (1)
  • Does it really make sense? We

Speaker 1

love

Passages & reports (1)
  • love

Speaker 2

platforms,

Passages & reports (1)
  • platforms,

Speaker 1

if we can get platforms, but we have the firepower to do an advanced product or an early stage. So we

Passages & reports (1)
  • if we can get platforms, but we have the firepower to do an advanced product or an early s…

Speaker 2

are sort of agnostic. We don't really manage our BD in that, hey, we need to fill ?a phase two slot or phase three slot. We're looking

Passages & reports (3)
  • are sort of agnostic. We don't really manage our BD in that, hey, we need to fill
  • a
  • phase two slot or phase three slot. We're looking

Speaker 1

for things that can make a difference to patients

Passages & reports (1)
  • for things that can make a difference to patients

Speaker 2

and

Passages & reports (1)
  • and

Speaker 1

build and interact better with and be better with us than they might be by themselves. I think to add to what Len just said, I think that every company looks internally and externally and tries to evaluate which are the best opportunities for them to take ?on. And unfortunately for most companies, they end up deciding that they have to look outside for the best opportunities compared to what's coming through the pipeline.

As Len just described, most of the time when we compare almost all external opportunities to what we have coming internally from our RD engine, we choose to focus
to spend our resources on the internal opportunities when we compare them to what we get from the outside. If you evaluate the track history of the industry in lit in licensing outside opportunities, uh I think you would you would realize that our our track record tends to outperform uh the industry's standards for in licensing by far.

Passages & reports (5)
  • build and interact better with and be better with us than they might be by themselves. I t…
  • on.
  • And unfortunately for most companies, they end up deciding that they have to look outside …
  • to spend our resources on the internal opportunities when we compare them to what we get f…
  • industry's standards for in licensing by far.

Speaker 2

Good point.

Passages & reports (1)
  • Good point.

Speaker unclear

?Thank

Passages & reports (1)
  • Thank

Speaker 1

you. Let's move to the next question, please, Shannon.

Passages & reports (1)
  • you. Let's move to the next question, please, Shannon.

Speaker 0

Thank you. Our next question comes from the line of June Lee with UBS. Your line is now open.

Passages & reports (1)
  • Thank you. Our next question comes from the line of June Lee with UBS. Your line is now op…

Speaker 7

Hi, uh congrats on a very strong quarter and uh thanks for taking our questions. You have four very promising next end dupeies based on patent filings. Um do you need just one to succeed or do you have plans different uh plans for different antibodies uh for different indications? Thank

Passages & reports (1)
  • Hi, uh congrats on a very strong quarter and uh thanks for taking our questions. You have …

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 1

That's that's a that's a great question. Uh I think that one of the reasons that we have these four assets is that we can actually imagine, as you say, that some might be better tailored for one setting versus another setting. And so our development plan is certainly anticipating that possibility.

Passages & reports (1)
  • That's that's a that's a great question. Uh I think that one of the reasons that we have t…

Speaker unclear

?Okay,

Passages & reports (1)
  • Okay,

Speaker 1

thank you. Next question, please.

Passages & reports (1)
  • thank you. Next question, please.

Speaker 0

Our next question comes from the line of Tizine Ahmad with Bank of America. Your line is now open.

Passages & reports (1)
  • Our next question comes from the line of Tizine Ahmad with Bank of America. Your line is n…

Speaker 5

Hi, good morning. Thanks for taking my question. ?I just wanted to get your updated view on the competitive landscape in A D, especially as it relates to next gen assets. You've talked about the importance of having long acting treatment. Do you think that's going to be sufficient to be competitive in the long run, just given that others might also try to have similar dosing frequencies, or do you think showing improved efficacy over dupey is also going to be needed?

Thanks.

Passages & reports (4)
  • Hi, good morning. Thanks for taking my question.
  • I
  • just wanted to get your updated view on the competitive landscape in A D, especially as it…
  • have similar dosing frequencies, or do you think showing improved efficacy over dupey is a…

Speaker 2

Well, let Ma Marine comment on the commercial side, ?but showing efficacy uh over dupey uh reminds me of the number of people that have tried to show efficacy over ILEA over the last 15 years. Very difficult to do, ?and I think the same will be true for our side B and other things that George talked about, because when you get to the heart of a problem, it's tough to really improve on mechanism.

That said, uh, I think while others might be able to do long acting, as we are, there's room for
multiple entries in this space, but very few will have the experience, the leverage, the capabilities ?that Santa Fe and Regenerar put together with their experience with Dupey. I don't know, Marion, if you'd like to.

Passages & reports (8)
  • Well, let Ma Marine comment on the commercial side,
  • but
  • showing efficacy uh over dupey uh reminds me of the number of people that have tried to sh…
  • and
  • I think the same will be true for our side B and other things that George talked about, be…
  • multiple entries in this space, but very few will have the experience, the leverage, the c…
  • that
  • Santa Fe and Regenerar put together with their experience with Dupey. I don't know, Marion…

Speaker 3

Well, let me just add what

Passages & reports (1)
  • Well, let me just add what

Speaker 1

one point to the competition. So, and I think it's a really, really important point. In order to achieve long acting, if you look at the competition, they're using heavily human-engineered versions of previously existing old antibodies that were generated decades ago. And when history shows, if you look across the industry, human engineering generally results in more problems than advances in terms of issues, for example, with drug antibodies and so forth.

So our approaches, remember, depend on a very
natural system, all derived naturally from our almost magical genetically engineered mouse that's fully humanized that delivers these, requiring almost no human intervention and engineering. So history shows, based on our own track record, that our naturally derived antibodies tend to outperform heavily engineered antibodies. So while others are trying to do what we're doing, uh we'll have to see how these heavily engineered versions will compare to what we've historically delivered and tend to perform very well in patients. ?

Go
ahead, Mary.

Passages & reports (6)
  • one point to the competition. So, and I think it's a really, really important point. In or…
  • And when history shows, if you look across the industry, human engineering generally resul…
  • natural system, all derived naturally from our almost magical genetically engineered mouse…
  • naturally derived antibodies tend to outperform heavily engineered antibodies. So while ot…
  • Go
  • ahead, Mary.

Speaker 4

So from commercialization, it's the platform that George and Len describe on the differentiation of our science, which results in efficacy, safety, and potential advancements on dosing frequency. But today it starts with depiction. We're across you know nine indications, age groups, geographies. depicts in time and time again has shown itself to be the product with best efficacy across type 2 diseases, remarkable safety, and tremendous results for patients.

So from a commercialization standpoint, we look forward to these next programs. As George described, it all starts with the differentiation of our signs.

Passages & reports (2)
  • So from commercialization, it's the platform that George and Len describe on the different…
  • shown itself to be the product with best efficacy across type 2 diseases, remarkable safet…

Speaker 1

Thank you. Next question, please, Shannon.

Passages & reports (1)
  • Thank you. Next question, please, Shannon.

Speaker 0

Our next question comes from the line of Ellie Merle with Barclays. Your line is now open.

Passages & reports (1)
  • Our next question comes from the line of Ellie Merle with Barclays. Your line is now open.

Speaker 4

Hey guys, thanks for taking the ?question and congrats

Passages & reports (3)
  • Hey guys, thanks for taking the
  • question and
  • congrats

Speaker unclear

?on

Passages & reports (1)
  • on

Speaker 3

the quarter. On the MASH program, interesting on the 70% liver fat reduction, and we certainly agree that MASH is a very large opportunity. Curious your perspective on the antifibrotic mechanism that you might be seeing here. ?And how are you thinking about this in the context of the FGF 21 class? ?I guess from your look at the genetics, did these point to a mechanistic rationale and F4 cirrhosis, or would you be focused more on the F2, F3 fibrosis setting.

And then you alluded to moving
?into registrational studies here. I know there's been an evolving discussion at the FDA on non-invasive markers versus histologic endpoints. Just curious your perspective and strategy here and thinking about the target patient population and potential next steps. Thanks.

Passages & reports (7)
  • the quarter. On the MASH program, interesting on the 70% liver fat reduction, and we certa…
  • And
  • how are you thinking about this in the context of the FGF 21 class?
  • I
  • guess from your look at the genetics, did these point to a mechanistic rationale and F4 ci…
  • into
  • registrational studies here. I know there's been an evolving discussion at the FDA on non-…

Speaker 1

It was a little hard to hear you, ?and it was a lot of questions in there. But the bottom line, and you can read our published data on the genetics. In terms of this pathway, it seems to protect against multiple aspects of liver disease, including that driven by fat, but by other mechanisms as well, with the effects represented in all facets of the resulting subsequent liver disease.

So we feel that this mechanism may be getting at the heart and driving of many aspects of the liver disease that the world would like to

Passages & reports (4)
  • It was a little hard to hear you,
  • and
  • it was a lot of questions in there. But the bottom line, and you can read our published da…
  • facets of the resulting subsequent liver disease. So we feel that this mechanism may be ge…

Speaker 3

be preventing.

Passages & reports (1)
  • be preventing.

Speaker 1

And no other pathway has shown this sort of genetic protection profile. So that's what makes it so exciting, together with the fact that ?the early clinical data actually are mirroring what we see genetically, which is giving us even more confidence in the genetics. In terms of registrational trials, as we said, we ?are moving aggressively forward in this program, and we'll be talking more at the November 10th roundtable where we can give you a lot more details.

Thanks, George. Next question, please, Shannon.

Passages & reports (5)
  • And no other pathway has shown this sort of genetic protection profile. So that's what mak…
  • the
  • early clinical data actually are mirroring what we see genetically, which is giving us eve…
  • are
  • moving aggressively forward in this program, and we'll be talking more at the November 10t…

Speaker 0

Our next question comes from the line of Gregory Renzo with Truist Securities. Your line is now open.

Passages & reports (1)
  • Our next question comes from the line of Gregory Renzo with Truist Securities. Your line i…

Speaker 7

Greg, good

Passages & reports (1)
  • Greg, good

Speaker 3

morning, everyone.

Passages & reports (1)
  • morning, everyone.

Speaker unclear

?Congrats on

Passages & reports (1)
  • Congrats on

Speaker 7

a tremendous

Passages & reports (1)
  • a tremendous

Speaker 3

quarter and thanks thanks for taking

Passages & reports (1)
  • quarter and thanks thanks for taking

Speaker unclear

?my question.

Passages & reports (1)
  • my question.

Speaker 7

presenting a challenge or even a risk to the execution

Passages & reports (1)
  • presenting a challenge or even a risk to the execution

Speaker 3

and

Passages & reports (1)
  • and

Speaker 7

the depth that you want Regeneron to have? And maybe relatedly, as you talk about uh electrorepitite and opening up a 3,000 patient trial, to what extent are are you and the team willing to make an investment in the in the vast uh obesity space and the resources that are in demand for uh winning there? Thanks so

Passages & reports (2)
  • the depth that you want Regeneron to have? And maybe relatedly, as you talk about uh elect…
  • winning there? Thanks so

Speaker unclear

?much.

Passages & reports (1)
  • much.

Speaker 2

Very good question, Greg. It seems it seems as though you may have been sitting in on some of our internal discussions. Um, this is something that

Passages & reports (1)
  • Very good question, Greg. It seems it seems as though you may have been sitting in on some…

Speaker 1

concerns us a ?lot. Um, how do we make sure

Passages & reports (3)
  • concerns us a
  • lot.
  • Um, how do we make sure

Speaker 2

uh that our best in class opportunities and drugs get adequately developed, uh compete well both in the development as well as

Passages & reports (1)
  • uh that our best in class opportunities and drugs get adequately developed, uh compete wel…

Speaker 1

commercialization? I can tell you we are

Passages & reports (1)
  • commercialization? I can tell you we are

Speaker 2

very focused

Passages & reports (1)
  • very focused

Speaker 1

on

Passages & reports (1)
  • on

Speaker 2

that, um, but our experience matters as uh

Passages & reports (1)
  • that, um, but our experience matters as uh

Speaker 1

I think

Passages & reports (1)
  • I think

Speaker 2

we try to get across. We have developed drugs for eye diseases, for

Passages & reports (1)
  • we try to get across. We have developed drugs for eye diseases, for

Speaker 1

cancer, for opt for um endocrinology,

Passages & reports (1)
  • cancer, for opt for um endocrinology,

Speaker 2

for um ENT, for gastroenterology, for uh uh allergists and so forth, pulmonologists. We have this experience of working with the specialists that we need to. We have

Passages & reports (1)
  • for um ENT, for gastroenterology, for uh uh allergists and so forth, pulmonologists. We ha…

Speaker 1

a great diverse group that George leaves internally. Uh I think we can do it. Doesn't mean we're gonna be perfect, but we are gonna strive to anything we take on, we're gonna take on wholeheartedly. We have ?the things CD. And I think we do now have the experience that it's going to take. George, you want to add to that?

Passages & reports (3)
  • a great diverse group that George leaves internally. Uh I think we can do it. Doesn't mean…
  • the things
  • CD. And I think we do now have the experience that it's going to take. George, you want to…

Speaker unclear

?Yeah,

Passages & reports (1)
  • Yeah,

Speaker 3

I remind you, not only are we

Passages & reports (1)
  • I remind you, not only are we

Speaker 1

working with all these specialists across these areas,

Passages & reports (1)
  • working with all these specialists across these areas,

Speaker 3

in many, if not most of

Passages & reports (1)
  • in many, if not most of

Speaker 1

those cases, we have the world's leading biologic that's utilized by these specialists. And the reason why is a combination of the fact that

Passages & reports (1)
  • those cases, we have the world's leading biologic that's utilized by these specialists. An…

Speaker 3

we are providing what ?we believe is best in class, often first in class, medicines for

Passages & reports (3)
  • we are providing what
  • we
  • believe is best in class, often first in class, medicines for

Speaker 1

our

Passages & reports (1)
  • our

Speaker 3

commercial team to

Passages & reports (1)
  • commercial team to

Speaker 1

then explain

Passages & reports (1)
  • then explain

Speaker 3

and

Passages & reports (1)
  • and

Speaker 1

deliver to these various specialists.

Passages & reports (1)
  • deliver to these various specialists.

Speaker 3

So

Passages & reports (1)
  • So

Speaker 1

when

Passages & reports (1)
  • when

Speaker 3

you talk about,

Passages & reports (1)
  • you talk about,

Speaker 1

for example, obesity, we don't want to just compete with just another obesity

Passages & reports (1)
  • for example, obesity, we don't want to just compete with just another obesity

Speaker unclear

?agent where we're maybe

Passages & reports (1)
  • agent where we're maybe

Speaker 3

fighting that we might

Passages & reports (1)
  • fighting that we might

Speaker unclear

?have one or two percent

Passages & reports (1)
  • have one or two percent

Speaker 3

more, you know, more weight loss or something like that. We want

Passages & reports (1)
  • more, you know, more weight loss or something like that. We want

Speaker unclear

?to deliver once again something that's truly

Passages & reports (1)
  • to deliver once again something that's truly

Speaker 1

differentiated. ?And that's what we're striving to do. For example,

Passages & reports (3)
  • differentiated.
  • And
  • that's what we're striving to do. For example,

Speaker unclear

?a

Passages & reports (1)
  • a

Speaker 3

weight loss agent that not only causes similar weight loss to all the other weight loss agents, but also by a completely different mechanism of

Passages & reports (1)
  • weight loss agent that not only causes similar weight loss to all the other weight loss ag…

Speaker 1

action,

Passages & reports (1)
  • action,

Speaker 3

dramatically lowers your lipids and your cardiovascular risk. We also have other approaches that we're combining with our obesity agent to prevent the profound loss of muscle that's caused by many of these obesity

Passages & reports (1)
  • dramatically lowers your lipids and your cardiovascular risk. We also have other approache…

Speaker 1

agents. And on and on. So if we're

Passages & reports (1)
  • agents. And on and on. So if we're

Speaker unclear

?entering the

Passages & reports (1)
  • entering the

Speaker 3

space,

Passages & reports (1)
  • space,

Speaker 1

our

Passages & reports (1)
  • our

Speaker unclear

?goal

Passages & reports (1)
  • goal

Speaker 3

is not to just

Passages & reports (1)
  • is not to just

Speaker unclear

?compete commercially with

Passages & reports (1)
  • compete commercially with

Speaker 1

the Me Too, but ?to give

Passages & reports (3)
  • the Me Too, but
  • to
  • give

Speaker unclear

?our commercial

Passages & reports (1)
  • our commercial

Speaker 3

group an agent ?that really makes a difference

Passages & reports (3)
  • group an agent
  • that really makes
  • a difference

Speaker unclear

?for

Passages & reports (1)
  • for

Speaker 1

patients,

Passages & reports (1)
  • patients,

Speaker 3

which they can then convey uh to the specialists that we're already dealing with who have already seen our ability to deliver game-changing

Passages & reports (1)
  • which they can then convey uh to the specialists that we're already dealing with who have …

Speaker unclear

?best

Passages & reports (1)
  • best

Speaker 1

in class medicines to their patients. Okay, thank you. I think we have time for two more questions, Shannon.

Passages & reports (1)
  • in class medicines to their patients. Okay, thank you. I think we have time for two more q…

Speaker 0

Thank you. Our next question comes from the line of Evan Siegerman with BMO Capital Markets. Your line is now open.

Passages & reports (1)
  • Thank you. Our next question comes from the line of Evan Siegerman with BMO Capital Market…

Speaker unclear

?Hi, thank you

Passages & reports (1)
  • Hi, thank you

Speaker 6

for taking my question. So the expanded Synopia Alliance adds, I think, four um next-gen antibodies focused on type two inflammation. What is the unmined need you're trying to solve that depicts and cannot? And should we think about these programs primarily as franchise expansion, life cycle protection, or ultimately replacement products? Thank

Passages & reports (1)
  • for taking my question. So the expanded Synopia Alliance adds, I think, four um next-gen a…

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 1

Good questions, Evan. Um I don't think this is the format where we really want to unveil our strategy. I think uh the Alliance has some very interesting ideas, uh, and I think you'll hear about them over ?time. Sorry to put that off, but I

Passages & reports (3)
  • Good questions, Evan. Um I don't think this is the format where we really want to unveil o…
  • time.
  • Sorry to put that off, but I

Speaker 2

do think uh

Passages & reports (1)
  • do think uh

Speaker unclear

?uh

Passages & reports (1)
  • uh

Speaker 1

there's a better form uh there's a

Passages & reports (1)
  • there's a better form uh there's a

Speaker 2

better uh format

Passages & reports (1)
  • better uh format

Speaker 1

for us to discuss this ?uh with Santa ?Fe. Okay, let's move to our final question please Shannon.

Passages & reports (5)
  • for us to discuss this
  • uh
  • with Santa
  • Fe.
  • Okay, let's move to our final question please Shannon.

Speaker 0

Our last question comes from the line of Alexandria Hammond with Wolf Research. Your line is now open.

Passages & reports (1)
  • Our last question comes from the line of Alexandria Hammond with Wolf Research. Your line …

Speaker unclear

?Thanks for squeezing me in. So on PNH, the

Passages & reports (1)
  • Thanks for squeezing me in. So on PNH, the

Speaker 0

ACS One cohort extension

Passages & reports (1)
  • ACS One cohort extension

Speaker unclear

?data versus ultimirus shows some really strong data. If you continue to replicate those efficacy results in the upcoming readout against Solaris, what are your

Passages & reports (1)
  • data versus ultimirus shows some really strong data. If you continue to replicate those ef…

Speaker 4

expectations

Passages & reports (1)
  • expectations

Speaker unclear

?on patient switching in the near term and steady state? I guess are there any nuances to this uh

Passages & reports (1)
  • on patient switching in the near term and steady state? I guess are there any nuances to t…

Speaker 7

patient population? We've heard them being characterized as sticky. Thank

Passages & reports (1)
  • patient population? We've heard them being characterized as sticky. Thank

Speaker unclear

?you.

Passages & reports (1)
  • you.

Speaker 2

Marion, you want to take that?

Passages & reports (1)
  • Marion, you want to take that?

Speaker 4

Happy to. So, you know, I do think that the the early clinical results have been very, very exciting and very compelling, but to the point we'll have to see additional clinical data differentiation. Um, but certainly we will look forward to bringing this particular product and indication into the marketplace.

Passages & reports (1)
  • Happy to. So, you know, I do think that the the early clinical results have been very, ver…

Speaker 1

Okay, thanks Marion. And thank you to everyone who dialed in for today's call. We apologize to those remaining in the Q and AQ who did not have a chance to ask their question. Today as always the investor relations team is available to answer any questions that that may remain. Thank you once again and have a great

Passages & reports (2)
  • Okay, thanks Marion. And thank you to everyone who dialed in for today's call. We apologiz…
  • and have a great

Speaker unclear

?day.

Passages & reports (1)
  • day.

Speaker 0

This concludes today's conference. Thank you for your participation. You may now disconnect.

Passages & reports (1)
  • This concludes today's conference. Thank you for your participation. You may now disconnec…
Source, accuracy & exportsMay contain errorsAccuracy unmeasured. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred. Speakers are anonymous voice labels, local to this call. No names are verified. Section starts and timestamps are inferred.

Short unclear spans may appear inline between matching voice IDs. The ? marker retains unknown attribution; no voice identity is inferred for those words.

AI-generated transcript; names, numbers and wording may be inaccurate.

Speaker IDs are anonymous and local to this call. Section boundaries and timestamps are inferred.

3 words have zero-duration alignments. Use surrounding audio; no timing has been repaired.

The diarizer reached its eight-speaker limit; distinct voices may share an ID.

Zero-duration alignments: 3. Unassigned words: 424. No alignment has been repaired. Timestamps locate passages in the source recording; decimal positions do not establish word-level precision.

Official issuer source ↗ · Report an issue

Published transcript · Full recording available. Publication updated 2026-11-16T00:27:53.970Z.
Transcript version v1-774a72b8f996010d5a2f · publication revision 1. Generated by AI; no listener-verified accuracy score is available.

Dotted spans marked ? have an unclear speaker. They remain unattributed even when shown inside a surrounding turn.

Copy or download
ReadableGrouped by speaker and paragraph with timestamps. Stored words unchanged.
As storedOne line per stored segment with its original speaker ID and start time. Exactly the stored words.
Official issuer source ↗Company overview ↗
TRANSCRIPT FEEDBACK

Report a passage

Your report is queued privately for review. It does not change this transcript automatically. Please avoid personal information.